NuVision Biotherapies is a clinical-stage biotherapies company focused on the treatment of ocular surface disease and eye injuries. Its proprietary technology harnesses the regenerative properties of amniotic membrane through its flagship products, Omnigen® and OmniLenz®, helping to support healing, reduce inflammation and improve patient outcomes in a range of ophthalmic conditions.
Founded as a spin-out from the University of Nottingham, NuVision has established a strong reputation for innovation in ocular care, with its products used across hospitals in the UK and an expanding international distribution network. The company continues to grow its presence in global markets while developing accessible, clinically proven therapies that simplify treatment and improve patient care.
Meet the lead executive(s)
Subscribe for email updates
